<DOC>
	<DOCNO>NCT00643240</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody find cancer cell carry cancer-killing substance without harm normal cell . This may effective treatment leukemia . PURPOSE : This phase I trial study best dose yttrium Y 90-labeled monoclonal antibody BU-12 treating patient advance relapsed refractory acute lymphoblastic leukemia chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Yttrium Y 90 Anti-CD19 Antibody BU-12 Patients With Advanced Relapsed Refractory Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine biodistribution indium-111 BU-12 patient refractory CD19+ leukemia . Secondary - To determine maximum tolerate dose yttrium Y 90 anti-CD19 antibody BU-12 - Determine human anti-mouse antibody ( HAMA ) response . - To define , preliminarily , antitumor activity yttrium Y 90 anti-CD19 antibody BU-12 . OUTLINE : Patients receive yttrium Y 90 anti-CD19 antibody BU-12/indium-111 BU-12 IV 60 minute day 0 undergo whole-body imaging day 0 , 1 , 3 , 4 , 7 . Patients also undergo blood collection bone marrow biopsy periodically dosimetry calculation pharmacokinetics . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm CD19positive ( &gt; 25 % flow cytometry evaluation bone marrow blast ) disease 1 follow type : Primary refractory relapse acute lymphoblastic leukemia ( ALL ) define persistent disease follow minimum two different standard effective chemotherapy induction attempt time diagnosis relapse Chronic Lymphocytic leukemia ( CLL ) follow blast crisis ( ≥15 % bone marrow blast follow minimum one standard effective chemotherapy induction attempt ) Human antimouse antibody ( HAMA ) must negative Patients relapse ≥ 60 day follow autologous allogeneic transplant eligible eligibility criterion meet No active central nervous system ( CNS ) disease ECOG performance status ( PS ) 02 Karnofsky PS 60100 % Life expectancy &gt; 8 week Total bilirubin ≤ 2.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine normal OR creatinine clearance ≥ 60 mL/min LVEF ≥ 45 % MUGA/ECHO Oxygen saturation room air &gt; 92 % oxygen requirement Not pregnant nursing Negative pregnancy test Fertile patient mus use effective contraception Exclusion criterion : History allergic reaction attribute compound similar chemical biologic composition yttrium Y 90 antiCD19 antibody BU12 agent use study Uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement HIVpositive Active graftvshost disease Less 4 week since prior agent recover Less 7 day since prior therapy biologic agent , define growth factor cytokine Less 3 month since prior antibody biologic anticancer therapy ( e.g. , alemtuzumab epratuzumab ) Other concurrent investigational agent Patients peripheral blast &gt; 5,000/uL may receive concurrent hydroxyurea</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>